Lipocine (LPCN) Receivables - Net (2022 - 2023)
Lipocine's (LPCN) quarterly Receivables - Net came in at $710000.0 in Q4 2023, down 81.47% YoY from $3.8 million in Q4 2022, and up 22.41% on a QoQ basis from $580000.0 in Q3 2023.
Lipocine (LPCN) Receivables - Net (2022 - 2023) Analysis & Trends
Lipocine (LPCN) has 2 years of Receivables - Net data on file, last reported at $710000.0 in Q4 2023.
- Quarterly Receivables - Net fell 81.47% year-over-year to $710000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $710000.0 (down 81.47% YoY) and the FY2023 annual result came in at $710000.0, down 81.47% from the prior year.
- Receivables - Net climbed to $710000.0 in Q4 2023, from $580000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $3.8 million in Q4 2022 to a low of $580000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | Lipocine | 11.37 Mn | -12.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 710,000.00 |
| Dec 31, 2023 | 710,000.00 |
| Sep 30, 2023 | 580,000.00 |
| Sep 30, 2023 | 580,000.00 |
| Dec 31, 2022 | 3.83 Mn |
| Dec 31, 2022 | 3.83 Mn |